Breast Cancer – Risk of Recurrence
Tests to assess breast cancer recurrence risk
Oncotype DX® Breast Cancer Assay
The Oncotype DX® Breast Cancer Assay can help physicians and patients decide on the best course of treatment. For invasive breast cancer, the Oncotype DX Breast Cancer Assay predicts chemotherapy benefit and the likelihood of distant breast cancer recurrence. The Oncotype DX Breast Cancer Assay for DCIS patients predicts the risk of local recurrence.
Test available from: precision oncology (or your oncologist in Ireland)
MammaPrint
Agendia’s MammaPrint is a test which determines how aggressive a breast cancer tumour is. The MammaPrint result will enable your physician to determine what would be the best kind of treatment for you following your operation.
Test available from: Agendia.com (through your physician).
Prosigna™
Available from: Nanostring Technologies (through your physician).
Prosigna provides a risk category and numerical score for assessment of the risk of distant recurrence of disease at 10 years in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), hormone receptor-positive (HR+) breast cancer.
The Prosigna Assay will be available for diagnostic use when ordered by a physician in the U.S. The Prosigna Assay has been CE-marked and is available for use by healthcare professionals in the European Union and other countries that recognize the CE Mark and in which Prosigna is registered. Source: Nanostring Technologies
EndoPredict
EndoPredict is a genomic test that accurately predicts the risk of recurrence in early-stage ER-positive, HER2-negative (ER+/HER2–) breast cancer – up to 15 years after diagnosis.1,2 It also indicates whether a patient is likely to benefit from chemotherapy,3,4 helping guide truly personalized treatment decisions.
Test available from: eurobio scientific
Page last updated January 2026